Solid Biosciences Inc. Increase (Decrease) in Accounts Payable
Solid Biosciences Inc. (SLDB) reported Increase (Decrease) in Accounts Payable of $1.14 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-06
- Solid Biosciences Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$1.18M, a 19800.00% decline year-over-year.
- Solid Biosciences Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $2.32M, a 403.47% increase year-over-year.
- Solid Biosciences Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$5.26M, a 745.03% decline year-over-year.
- Solid Biosciences Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $3.70M, a 302.72% increase year-over-year.
- Solid Biosciences Inc. increase (decrease) in accounts payable for fiscal 2025 was -$1.09M, a 149.57% decline from fiscal 2024.
- Solid Biosciences Inc. increase (decrease) in accounts payable for fiscal 2024 was $2.21M.
- Solid Biosciences Inc. increase (decrease) in accounts payable for fiscal 2023 was -$764.00K.
- Solid Biosciences Inc. increase (decrease) in accounts payable for fiscal 2022 was -$5.25M, a 533.91% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.14M 10-Q · filed 2026-08-06 | -$4.12M derived: sum of 3 quarters · filed 2026-08-06 | -$421.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.32M 10-Q · filed 2026-05-12 | -$2.94M derived: sum of 2 quarters · filed 2026-05-12 | $761.00K derived: sum of 3 quarters · filed 2026-05-12 | $767.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$5.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$1.56M derived: sum of 2 quarters · filed 2026-03-19 | -$1.55M derived: sum of 3 quarters · filed 2026-08-06 | -$1.09M 10-K · filed 2026-03-19 |
| 2025-09-30 | $3.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $3.70M derived: sum of 2 quarters · filed 2026-08-06 | $4.16M 10-Q · filed 2025-11-03 | $4.98M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $467.00K 10-Q · filed 2026-08-06 | $1.28M derived: sum of 3 quarters · filed 2026-08-06 | $2.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $461.00K 10-Q · filed 2026-05-12 | $1.28M derived: sum of 2 quarters · filed 2026-05-12 | $2.19M derived: sum of 3 quarters · filed 2026-05-12 | $3.26M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $815.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $1.73M derived: sum of 2 quarters · filed 2026-03-19 | $2.80M derived: sum of 3 quarters · filed 2026-03-19 | $2.21M 10-K · filed 2026-03-19 |
| 2024-09-30 | $918.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $1.99M derived: sum of 2 quarters · filed 2025-11-03 | $1.39M 10-Q · filed 2025-11-03 | $1.52M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $1.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $472.00K 10-Q · filed 2025-08-12 | $606.00K derived: sum of 3 quarters · filed 2025-08-12 | -$323.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$596.00K 10-Q · filed 2025-05-15 | -$462.00K derived: sum of 2 quarters · filed 2025-05-15 | -$1.39M derived: sum of 3 quarters · filed 2025-05-15 | -$4.11M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $134.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$795.00K derived: sum of 2 quarters · filed 2025-03-06 | -$3.51M derived: sum of 3 quarters · filed 2025-03-06 | -$764.00K 10-K · filed 2025-03-06 |
| 2023-09-30 | -$929.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$3.64M derived: sum of 2 quarters · filed 2024-11-06 | -$898.00K 10-Q · filed 2024-11-06 | -$6.80M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$2.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $31.00K 10-Q · filed 2024-08-13 | -$5.88M derived: sum of 3 quarters · filed 2024-08-13 | -$5.59M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $2.75M 10-Q · filed 2024-05-15 | -$3.16M derived: sum of 2 quarters · filed 2024-05-15 | -$2.87M derived: sum of 3 quarters · filed 2024-05-15 | -$2.57M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$5.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$5.62M derived: sum of 2 quarters · filed 2024-03-13 | -$5.32M derived: sum of 3 quarters · filed 2024-03-13 | -$5.25M 10-K · filed 2024-03-13 |
| 2022-09-30 | $287.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $589.00K derived: sum of 2 quarters · filed 2023-11-08 | $660.00K 10-Q · filed 2023-11-08 | $1.23M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-06-30 | $302.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $373.00K 10-Q · filed 2023-08-14 | $943.00K derived: sum of 3 quarters · filed 2024-03-13 | $1.90M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-03-31 | $71.00K 10-Q · filed 2023-05-11 | $641.00K derived: sum of 2 quarters · filed 2024-03-13 | $1.60M derived: sum of 3 quarters · filed 2024-03-13 | $1.37M derived: sum of 4 quarters · filed 2024-03-13 |
| 2021-12-31 | $570.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $1.53M derived: sum of 2 quarters · filed 2024-03-13 | $1.30M derived: sum of 3 quarters · filed 2024-03-13 | $1.21M 10-K · filed 2024-03-13 |
| 2021-09-30 | $957.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $729.00K derived: sum of 2 quarters · filed 2022-11-10 | $639.00K 10-Q · filed 2022-11-10 | -$190.00K derived: sum of 4 quarters · filed 2023-03-23 |
| 2021-06-30 | -$228.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$318.00K 10-Q · filed 2022-08-11 | -$1.15M derived: sum of 3 quarters · filed 2023-03-23 | $143.00K derived: sum of 4 quarters · filed 2023-03-23 |
| 2021-03-31 | -$90.00K 10-Q · filed 2022-04-27 | -$919.00K derived: sum of 2 quarters · filed 2023-03-23 | $371.00K derived: sum of 3 quarters · filed 2023-03-23 | $788.00K derived: sum of 4 quarters · filed 2023-03-23 |
| 2020-12-31 | -$829.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $461.00K derived: sum of 2 quarters · filed 2023-03-23 | $878.00K derived: sum of 3 quarters · filed 2023-03-23 | -$3.43M 10-K · filed 2023-03-23 |
| 2020-09-30 | $1.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $1.71M derived: sum of 2 quarters · filed 2021-11-03 | -$2.60M 10-Q · filed 2021-11-03 | $1.17M derived: sum of 4 quarters · filed 2022-03-14 |
| 2020-06-30 | $417.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$3.89M 10-Q · filed 2021-08-16 | -$121.00K derived: sum of 3 quarters · filed 2022-03-14 | -$2.55M derived: sum of 4 quarters · filed 2022-03-14 |
| 2020-03-31 | -$4.31M 10-Q · filed 2021-05-14 | -$538.00K derived: sum of 2 quarters · filed 2022-03-14 | -$2.97M derived: sum of 3 quarters · filed 2022-03-14 | -$2.20M derived: sum of 4 quarters · filed 2022-03-14 |
| 2019-12-31 | $3.77M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $1.34M derived: sum of 2 quarters · filed 2022-03-14 | $2.11M derived: sum of 3 quarters · filed 2022-03-14 | $3.78M 10-K · filed 2022-03-14 |
| 2019-09-30 | -$2.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$1.66M derived: sum of 2 quarters · filed 2020-11-05 | $8.00K 10-Q · filed 2020-11-05 | -$1.50M derived: sum of 4 quarters · filed 2021-03-15 |
| 2019-06-30 | $771.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $2.44M 10-Q · filed 2020-08-06 | $934.00K derived: sum of 3 quarters · filed 2021-03-15 | $1.88M derived: sum of 4 quarters · filed 2021-03-15 |
| 2019-03-31 | $1.67M 10-Q · filed 2020-05-07 | $163.00K derived: sum of 2 quarters · filed 2021-03-15 | $1.11M derived: sum of 3 quarters · filed 2021-03-15 | $410.00K derived: sum of 4 quarters · filed 2021-03-15 |
| 2018-12-31 | -$1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | -$553.00K derived: sum of 2 quarters · filed 2021-03-15 | -$1.26M derived: sum of 3 quarters · filed 2021-03-15 | -$1.61M 10-K · filed 2021-03-15 |
| 2018-09-30 | $950.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $247.00K derived: sum of 2 quarters · filed 2019-11-12 | -$107.00K 10-Q · filed 2019-11-12 | -$807.00K derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | -$703.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | -$1.06M 10-Q · filed 2019-08-14 | -$1.76M derived: sum of 3 quarters · filed 2020-03-12 | $1.79M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | -$354.00K 10-Q · filed 2019-05-13 | -$1.05M derived: sum of 2 quarters · filed 2020-03-12 | $2.49M derived: sum of 3 quarters · filed 2020-03-12 | $393.00K derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | -$700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $2.84M derived: sum of 2 quarters · filed 2020-03-12 | $747.00K derived: sum of 3 quarters · filed 2020-03-12 | $1.58M 10-K · filed 2020-03-12 |
| 2017-09-30 | $3.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $1.45M derived: sum of 2 quarters · filed 2018-11-13 | $2.28M 10-Q · filed 2018-11-13 | |
| 2017-06-30 | -$2.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10 | -$1.26M 10-Q · filed 2018-08-10 | ||
| 2017-03-31 | $832.00K 10-Q · filed 2018-05-10 | |||
| 2016-12-31 | $2.21M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |